Bausch Health Cos (BHC) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Bausch Health Cos (NYSE:BHC) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Do insiders and institutionals believe in BPMC or BHC?

78.7% of Bausch Health Cos shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 8.1% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts prefer BPMC or BHC?

Blueprint Medicines currently has a consensus price target of $128.06, indicating a potential downside of 0.16%. Bausch Health Cos has a consensus price target of $7.42, indicating a potential upside of 6.73%. Given Bausch Health Cos' higher possible upside, analysts plainly believe Bausch Health Cos is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.27
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

Which has stronger valuation and earnings, BPMC or BHC?

Bausch Health Cos has higher revenue and earnings than Blueprint Medicines. Bausch Health Cos is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$508.82M	16.28	-$67.09M	-$2.47	-51.93
Bausch Health Cos	$9.63B	0.27	-$46M	-$0.11	-63.17

Is BPMC or BHC more profitable?

Bausch Health Cos has a net margin of -0.41% compared to Blueprint Medicines' net margin of -27.70%. Blueprint Medicines' return on equity of -64.60% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-27.70%	-64.60%	-17.22%
Bausch Health Cos	-0.41%	-540.45%	5.26%

Does the media favor BPMC or BHC?

In the previous week, Blueprint Medicines had 4 more articles in the media than Bausch Health Cos. MarketBeat recorded 5 mentions for Blueprint Medicines and 1 mentions for Bausch Health Cos. Blueprint Medicines' average media sentiment score of 0.81 beat Bausch Health Cos' score of 0.23 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, BPMC or BHC?

Blueprint Medicines has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Summary

Blueprint Medicines beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.